OnKure Therapeutics (OKUR) News Today $2.51 +0.01 (+0.40%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$2.58 +0.07 (+2.75%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period OnKure Therapeutics (OKUR) to Release Earnings on TuesdayMay 5 at 3:06 AM | americanbankingnews.comOnKure Therapeutics (NASDAQ:OKUR) Receives Average Rating of "Buy" from AnalystsMay 5 at 2:15 AM | americanbankingnews.comWhat is Leerink Partnrs' Forecast for OKUR Q1 Earnings?May 3 at 1:42 AM | americanbankingnews.comOnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock NewsApril 30, 2025 | gurufocus.comOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comAisling Capital Management LP Invests $762,000 in OnKure Therapeutics (NASDAQ:OKUR)Aisling Capital Management LP bought a new stake in OnKure Therapeutics (NASDAQ:OKUR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 88,607 shares of the company's stock, valued at approximately $762,April 3, 2025 | marketbeat.comHighbridge Capital Management LLC Makes New $3.44 Million Investment in OnKure Therapeutics (NASDAQ:OKUR)Highbridge Capital Management LLC bought a new stake in OnKure Therapeutics (NASDAQ:OKUR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 399,743 shares of the company's stock, valued at apprMarch 29, 2025 | marketbeat.comQ1 EPS Estimate for OnKure Therapeutics Decreased by AnalystOnKure Therapeutics (NASDAQ:OKUR - Free Report) - Equities researchers at HC Wainwright reduced their Q1 2025 EPS estimates for OnKure Therapeutics in a research report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.41) per shaMarch 21, 2025 | marketbeat.comOnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on ThursdayOnKure Therapeutics (NASDAQ:OKUR) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for OnKure Therapeutics (NASDAQ:OKUR) Stock PriceHC Wainwright dropped their target price on shares of OnKure Therapeutics from $40.00 to $34.00 and set a "buy" rating for the company in a research report on Tuesday.March 19, 2025 | marketbeat.comOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comPromising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025March 18, 2025 | tipranks.comWill OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?March 12, 2025 | finance.yahoo.comOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future ProspectsMarch 12, 2025 | tipranks.comOnKure Therapeutics Reports Progress and FinancialsMarch 12, 2025 | tipranks.comOnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)March 10, 2025 | markets.businessinsider.comOnKure Therapeutics price target lowered to $30 from $35 at OppenheimerMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Progress on PIKture-01 Trial and Expands PI3Ka Franchise with Upcoming Development Candidate AnnouncementMarch 10, 2025 | quiverquant.comOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | globenewswire.comOnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor ConferencesMarch 4, 2025 | globenewswire.comDeep Track Capital, LP Acquires Shares in OnKure Therapeutics IncFebruary 14, 2025 | gurufocus.comHighbridge Capital Management LLC Acquires Significant Stake in OnKure Therapeutics IncFebruary 7, 2025 | gurufocus.comJonesTrading Reaffirms Their Buy Rating on OnKure Therapeutics (OKUR)February 6, 2025 | markets.businessinsider.comVanguard Group Inc's Strategic Acquisition of OnKure Therapeutics SharesJanuary 31, 2025 | gurufocus.comJones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy RecommendationJanuary 30, 2025 | msn.comOnKure Therapeutics initiated with a Buy at JonesResearchJanuary 29, 2025 | markets.businessinsider.comJones Trading sets OnKure stock Buy rating, $32 targetJanuary 29, 2025 | msn.comOnKure Therapeutics, Inc. (OKUR)January 7, 2025 | finance.yahoo.comOnKure Therapeutics Inc Class A Shares OKURDecember 22, 2024 | morningstar.comOppenheimer Remains a Buy on OnKure Therapeutics (OKUR)December 12, 2024 | markets.businessinsider.comOnKure Therapeutics announces safety, pharmacokinetic data on OKI-219December 11, 2024 | markets.businessinsider.comOnKure Therapeutics Reports Positive Preliminary Data From First-in-human Study Of OKI-219December 10, 2024 | markets.businessinsider.comOnKure Therapeutics Advances Cancer Drug TrialsDecember 10, 2024 | tipranks.comOnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219December 10, 2024 | globenewswire.comLeerink Partners Initiates Coverage of OnKure Therapeutics (OKUR) with Outperform RecommendationDecember 5, 2024 | msn.comOnKure Therapeutics Inc Class A SharesDecember 5, 2024 | morningstar.comOnKure Therapeutics Reports Strategic Merger and Financial UpdatesNovember 26, 2024 | markets.businessinsider.comOnKure Announces New Date for Upcoming Investor CallNovember 25, 2024 | globenewswire.comOnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten GrowthNovember 9, 2024 | tipranks.comOnKure Therapeutics' (OKUR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of OnKure Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comOnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer SymposiumNovember 1, 2024 | globenewswire.comQ3 Earnings Forecast for OKUR Issued By HC WainwrightOnKure Therapeutics (NASDAQ:OKUR - Free Report) - Analysts at HC Wainwright issued their Q3 2024 earnings estimates for OnKure Therapeutics in a report released on Thursday, October 17th. HC Wainwright analyst R. Burns anticipates that the company will earn ($1.03) per share for the quarter. HC WOctober 21, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for OKUR Q1 Earnings?OnKure Therapeutics (NASDAQ:OKUR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for OnKure Therapeutics in a research report issued on Thursday, October 17th. HC Wainwright analyst R. Burns anticipates that the company will post earnings oOctober 18, 2024 | marketbeat.comOnKure Therapeutics (NASDAQ:OKUR) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a research report on Thursday.October 17, 2024 | marketbeat.com Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address OKUR Media Mentions By Week OKUR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKUR News Sentiment▼0.640.72▲Average Medical News Sentiment OKUR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKUR Articles This Week▼81▲OKUR Articles Average Week Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fate Therapeutics News Greenwich LifeSciences News Protara Therapeutics News Editas Medicine News Lyell Immunopharma News Theratechnologies News Tonix Pharmaceuticals News scPharmaceuticals News Sol-Gel Technologies News Compugen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKUR) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OKUR Stock Free OKUR Stock Alerts